This site is intended for healthcare professionals
adrenocortical carcinoma (ACC) webinar banner
onDemand webinar

Early and optimal management of adrenocortical carcinoma (ACC): webinar

Read time: 60 mins
Published:2nd Mar 2023

As the understanding of adrenocortical carcinoma (ACC) management progresses, join leading experts Professor Alfredo Berruti and Professor Jaydira Del Rivero in this webinar ‘Early and optimal management of ACC’.

This webinar intends to educate on:

  • Current guidelines and strategies for ACC management
  • Differences in managing patients at different disease stages and treatment sequencing
  • Optimal treatment side effect management

This hour-long webinar presents patient case studies with two experts and a Q&A session after each session. The content and agenda of the webinar is summarised below:

  1. Welcome and Introductions (~7 minutes)
    Professor Berruti introduces the webinar, case study format and provides and overview of challenges in ACC management.
  2. Session 1: Treatment algorithms in ACC – a patient case study (~10 minutes)
    Professor Berruti presents three patient case studies in which he explores clinical assessment and staging for ACC, treatment options and consideration for selection, and ACC treatment algorithms per guideline recommendations.
  3. Q&A Session 1 (~15 minutes)
    The first Q&A session of the webinar sees Professor Berruti and Professor Del Rivero discuss questions from the live audience on Session 1, considering ACC management and treatment selection.
  4. Session 2: Treatment combination side effects – a patient case study (~10 minutes)
    Professor Del Rivero presents three patient case studies, exploring efficacy and safety of ACC treatment combinations in patients undergoing chemotherapy and considerations for the management of side effects.
  5. Q&A Session 2 (~15 minutes)
    In the second Q&A session Professor Berruti and Professor Del Rivero discuss further questions from the live audience, this time focused on Session 2, considering side effect management strategies and treatment approaches.
  6. Key Takeaways and Closing Remarks (~3 minutes)
    Professor Berruti summarises the key takeaways from this live ACC webinar and brings the event to a close.


Professor Christopher Edwards.jpg

Professor Alfredo Berruti

Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Spedali Civili Hospital, Brescia, Italy.

Professor Alfredo Berruti is a full Professor of Medical Oncology at the University of Brescia, Director of the Oncology Unit and of the Oncology Department of the Spediali Civili Hospital in Brescia, Director of the School of Specialization in Oncology of the University of Brescia and Dean of Degree Course in Medicine and Surgery at University of Brescia.

Professor Christopher Edwards.jpg

Professor Jaydira Del Rivero

Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, United States; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, United States.

Professor Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center. Professor Del Rivero is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials. Professsor Del Rivero’s current efforts are the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma.

This content has been developed independently of the sponsor, HRA Pharma Rare Diseases, which has had no editorial input into the content. Medthority received educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.